Начало › Рак на кръвта › Тексас › Houston
Клинични проучвания за Рак на кръвта в Houston, TX
46 проучвания за Рак на кръвта търсят участници в обекти в и около Houston (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Набиране на участнициФаза 3
- University of Texas MD Anderson Cancer Center ( Site 0007), Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- UT MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Набиране на участнициНаблюдателно проучване
- Texas Children's Hospital, Houston
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Набиране на участнициФаза 1
- MD Anderson Cancer Center - University of Texas, Houston
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Набиране на участнициФаза 3
- Quetzal Site 6, Houston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Набиране на участнициФаза 1
- UT MD Anderson Cancer Center, Houston
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Набиране на участнициРанна фаза 1
- M D Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Набиране на участнициФаза 3
- The University of Texas MD Anderson Cancer Center, Houston
Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
Набиране на участнициНаблюдателно проучване
- UT MD Anderson Cancer Center, Houston
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Набиране на участнициФаза 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Набиране на участнициФаза 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Набиране на участнициФаза 1
- Md Anderson Cancer Center, Houston
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
Набиране на участници
- M D Anderson Cancer Center, Houston
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
Набиране на участнициФаза 2Здравите доброволци са добре дошли
- M D Anderson Cancer Center, Houston
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Набиране на участнициФаза 1
- M D Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Набиране на участнициФаза 1/2
- MD Anderson, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Набиране на участнициНаблюдателно проучване
- M D Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Набиране на участнициФаза 3
- University of Texas, Houston
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Набиране на участнициФаза 1/2
- M D Anderson Cancer Center, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Набиране на участнициРанна фаза 1
- M D Anderson Cancer Center, Houston
Expressive Writing for the Management of Stress in Cancer Survivors
Набиране на участници
- M D Anderson Cancer Center, Houston
The Impact of COVID-19 on Pulmonary Procedures
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- M D Anderson Cancer Center, Houston
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
Набиране на участнициНаблюдателно проучване
- M D Anderson Cancer Center, Houston
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Набиране на участнициФаза 2
- University of Texas MD Anderson MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Набиране на участнициФаза 1
- The University of TX MD Anderson Cancer Center, Houston
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Набиране на участнициФаза 2
- M D Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Набиране на участнициНаблюдателно проучване
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
Improving Comprehensive Care of Cancer Patients
Набиране на участнициЗдравите доброволци са добре дошли
- Baylor College of Medicine, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Набиране на участнициНаблюдателно проучване
- M D Anderson Cancer Center, Houston
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
Набиране на участнициНаблюдателно проучване
- M D Anderson Cancer Center, Houston
Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- M D Anderson Cancer Center, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Набиране на участнициНаблюдателно проучване
- M D Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Набиране на участнициФаза 2
- M D Anderson Cancer Center, Houston
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Набиране на участнициФаза 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
Набиране на участници
- M D Anderson Cancer Center, Houston
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
Набиране на участнициФаза 2
- The University of Texas M. D. Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Набиране на участнициФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies
Набиране на участнициНаблюдателно проучване
- M D Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Набиране на участнициФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Набиране на участнициФаза 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Проучвания за Рак на кръвта в други градове
- New York City, NY26 проучвания
- Boston, MA25 проучвания
- Washington, DC19 проучвания
- Baltimore, MD18 проучвания
- Seattle, WA18 проучвания
- Los Angeles, CA17 проучвания
- Durham, NC16 проучвания
- Chicago, IL15 проучвания
- Philadelphia, PA14 проучвания
- Atlanta, GA13 проучвания
- Nashville, TN13 проучвания
- Edison, NJ13 проучвания
Други проучвания в Houston
- Рак на белия дроб с недребноклетъчен тип145 проучвания
- Рак на гърдата126 проучвания
- Рак (всички видове)121 проучвания
- Метастатичен рак104 проучвания
- Колоректален рак102 проучвания
- Рак на яйчниците89 проучвания
- Остра миелоидна левкемия85 проучвания
- Рак на белия дроб78 проучвания
- Рак на простатата76 проучвания
- Ендометриален рак68 проучвания
- Рак на панкреаса61 проучвания
- Меланом59 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.